Loading data for CTOR — first visit, this takes a few seconds.

Citius Oncology, Inc. (CTOR)

NasdaqCM: CTOR · 即時價格 · USD

0.78

+0.00 (0.00%)

收盤價： Sep 01, 2026, 3:50 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	0.55
市值	79.3M
營收 (ttm)	7.11M
淨利（ttm）	-46.1M
	3.49
	-0.48
	n/a
	n/a
P/B (ttm)	1.96
P/S (ttm)	11.16
財報日期	n/a

賣價	1
成交量	15,479
20 日平均成交量	82,068
開盤價	0.82
前收盤價	0.78
當日區間	0.77 - 0.82
52 週範圍	0.49 - 2.25
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 CTOR

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc....

類股 Healthcare

IPO 日期 Dec 8, 2022

員工 n/a

證券交易所 NasdaqCM

股票代號 CTOR

網站 https://citiusonc.com/overview/default.aspx

完整的公司簡介

財務表現

Citius Oncology 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -24.76M，較前期增加 17.08%。

財務報表

財報驚奇

Citius Oncology 已於 Aug 14, 2026 公布季度財報：

營收為 $1.67M 低於預期 $0, 年增 Infinity% 成長.
每股盈餘為 -0.08 低於預期 -0.01, 年增 0.00% 成長.

價格為何變動

新聞動態

2 週前 · InvestorsHub

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.

3 月前 · Insider Monkey

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

With an upside potential of 843.40%, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 18, H.C. Wainwright analyst Sway...

4 月前 · Pharmaceutical Technology

Citius raises $36.5m for Lymphir commercialisation

The capital includes a $25m term loan and a warrant exercise agreement expected to yield $11.5m.

4 月前 · Simply Wall St.

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Citius Oncology, Inc. ( NASDAQ:CTOR ) is possibly approaching a major achievement in its business, so we would like to...

6 月前 · Insider Monkey

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following...

第 1 頁，共 2 頁

Citius Oncology, Inc. (CTOR)